Pharma BD Deal Intelligence
A cheap cleanup trade: Context Therapeutics paid BioAtla $6.5 million total ($4.5M upfront plus $2.0M due by August 1, 2026) to buy out all future milestones and royalties on CT-202, ahead of the bispecific's Phase 1 start.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Context Therapeutics (Nasdaq: CNTX) has paid USD 6.5 million to buy out all future milestone and royalty obligations on CT-202. The transaction restructured…
Context Therapeutics amended its license agreement with BioAtla regarding CT-202, a Nectin-4 x CD3 T cell engaging bispecific antibody. The agreement removes…
Context Therapeutics announced an amendment to its exclusive license agreement with BioAtla for CT-202, securing full rights to the Nectin-4 x CD3 bispecific…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Context Therapeutics amended its September 2024 exclusive license agreement with BioAtla for CT-202, a Nectin-4 x CD3 T cell engager bispecific antibody. Context bought out all future milestone and royalty obligations for a $4.5 million upfront payment plus a final $2.0 million payment due by August 1, 2026, in exchange for a fully paid-up, non-terminable license.
84K US cases/yr · $7.2B 2024 US ADC market (relevant solid-tumor segment proxy) · 0.6%-6.6% Nectin-4 amplification frequency across solid tumors (tumor-agnostic biomarker)
Nectin-4 is a type I transmembrane cell adhesion protein highly overexpressed in urothelial carcinoma and frequently amplified in bladder, colorectal, lung, and breast cancers. It is a validated cancer target — the Nectin-4 ADC enfortumab vedotin (with pembrolizumab) became standard of care for 1L metastatic urothelial cancer in 2023, but Nectin-4 amplification occurs broadly across solid tumors, creating a tumor-agnostic opportunity. T-cell engagers offer a distinct mechanism that may address EV-refractory disease.
Nectin-4 is currently dominated by enfortumab vedotin (Padcev, Astellas/Pfizer ADC) in 1L+2L urothelial cancer. Bispecific T-cell engagers targeting Nectin-4 x CD3 represent a next-wave approach — pH-dependent or conditional-activation TCEs aim to expand into EV-refractory tumors and non-urothelial Nectin-4+ indications. Competing TCE programs include Aptevo's Nectin-4 radiopharma collaboration with Niowave and several preclinical bispecifics from Chinese biotechs.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Context Therapeutics Inc. / BioAtla, Inc. (this deal) | 2026 | $6M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2026 deals · Oncology deals